BACKGROUND – Diabetic Retinopathy (DR) is most common microvascular complication in Diabetes patients. Increased VEGF production in retina of diabetic patient causes neovascular proliferation which extended to vitreous causing Vitreous Bleeding , fibrosis and retinal detachment leading to loss of vision. Systemic prolactin enters to the eye by prolactin receptor and proteolyzed into vasoinhibin which have anti-angiogenesis property by inhibiting Vascular endothelial growth factor (VEGF) , Protect against DR. This study aims to correlate the level of serum prolactin in DR patients.
METHODS – Serum prolactin was evaluated in 50 non-diabetic and 100 diabetic patients at various stage of DR at SCB Medical college and Hospital ,Cuttack from 2019-2020.
RESULTS – The serum prolactin is higher in patients of Diabetes without DR compared to both control non-diabetic and Diabetes with DR.
CONCLUSION - Higher serum prolactin level in Diabetes patients protect against DR after conversion into Vasoinhibin in Retina . Thus inducing hyperprolactinemia may act as a novel therapy against DR.